Today: 7 February 2026
Subscribe
Browse Category

Healthcare Stocks News 30 October 2025 - 4 December 2025

Incannex Healthcare (IXHL) Stock Soars on FDA Fast Track: December 2025 Outlook, Forecast & Key Risks

Incannex Healthcare (IXHL) Stock Soars on FDA Fast Track: December 2025 Outlook, Forecast & Key Risks

Incannex Healthcare Inc. (Nasdaq: IXHL) is back on traders’ radar after the U.S. Food and Drug Administration granted Fast Track designation to its lead sleep-apnoea drug candidate, IHL‑42X. The move caps a busy 2025 that also brought strong Phase 2 data in sleep apnoea and psilocybin-assisted therapy, a major clean-up of warrant overhang, and a fight to keep the company’s Nasdaq listing alive. SEC+1 As of the U.S. session on 4 December 2025, IXHL was trading around $0.48 per share, up roughly 8% on the day and extending a sharp two-day rebound following the Fast Track news. ChartMill Below is
4 December 2025
·····
Cardinal Health (CAH) Stock Pulls Back From Record Highs: Latest News, Forecasts and Investment Outlook as of December 3, 2025

Cardinal Health (CAH) Stock Pulls Back From Record Highs: Latest News, Forecasts and Investment Outlook as of December 3, 2025

Cardinal Health (NYSE: CAH) stock has cooled off after a powerful run in 2025, raising a key question for investors: is this just a healthy pullback, or the start of something more serious? Below is a detailed, news-driven look at Cardinal Health’s share price, fundamentals, analyst forecasts and key risks as of December 3, 2025. Cardinal Health Stock Today: Five Straight Losses After a Huge 2025 Rally At the close on Wednesday, December 3, 2025, Cardinal Health shares finished at $199.71, down 2.64% on the day. That decline came despite a positive session for the broader market, with the S&P
4 December 2025
·····
Smith & Nephew (SN, SNN) Stock Outlook for December 2025: Q3 Setback, $500m Buyback and What Comes Next

Smith & Nephew (SN, SNN) Stock Outlook for December 2025: Q3 Setback, $500m Buyback and What Comes Next

London – 2 December 2025 – Smith & Nephew plc (LSE: SN., NYSE: SNN) heads into the final weeks of 2025 as a classic “turnaround in progress” story: margins are rising, cash generation is strong and a $500 million buyback has been completed, yet the shares are still digesting a sharp sell‑off after a softer‑than‑hoped third quarter.Smith & Nephew+2TipRanks+2 Below is a detailed look at the latest share price action, Q3 numbers, analyst forecasts, activist pressure and the key catalysts investors are watching in December. Smith & Nephew share price today On the London Stock Exchange, Smith & Nephew shares
2 December 2025
······
HCA Healthcare (HCA) Stock on December 1, 2025: Near All‑Time Highs, Upgraded Guidance and What Comes Next

HCA Healthcare (HCA) Stock on December 1, 2025: Near All‑Time Highs, Upgraded Guidance and What Comes Next

Date: December 1, 2025 – NYSE: HCA HCA Healthcare stock snapshot on December 1, 2025 HCA Healthcare, Inc. (NYSE: HCA), the largest for‑profit hospital operator in the United States, continues to trade near record territory as December begins. Barchart’s latest feature on the stock notes that HCA hit an all‑time high of $520 in the prior session and that shares have soared 71.5% year‑to‑date and 56.5% over the past 12 months, handily beating the Health Care Select Sector SPDR ETF (XLV). Barchart.com Technically, HCA has been trading above its 50‑day moving average since January and above its 200‑day moving average
1 December 2025
····
Johnson & Johnson (JNJ) Stock Near Record Highs: Is the $500 Billion Healthcare Giant Still a Buy in 2025?

Johnson & Johnson (JNJ) Stock Near Record Highs: Is the $500 Billion Healthcare Giant Still a Buy in 2025?

Updated: November 30, 2025 Johnson & Johnson stock has quietly turned into one of 2025’s big winners. After years of trading like a sleepy defensive name, JNJ has gone on an 11‑ to 13‑day winning streak, pushed its market capitalization to roughly $500 billion, and logged one of its strongest years since the mid‑1990s. Nai500 As of late November, Johnson & Johnson shares recently changed hands around $206–$208, not far from a fresh all‑time high close of $207.56 on November 26. That price leaves the stock up about 45% year‑to‑date, handily beating the S&P 500’s mid‑teens gain and reversing a
30 November 2025
····
Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Published: November 29, 2025 Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 riding a powerful wave of oncology wins, big‑ticket acquisitions and fresh analyst upgrades that have pushed the stock to new 52‑week highs. As of the close on Friday, November 28, Merck shares finished at $104.83, just off a record intraday high of $105.84 set earlier in the week.StockAnalysis+1 The stock is up roughly 21% over the past month and about 7–8% year‑to‑date, according to recent performance data and independent valuation analysis.Simply Wall St+2FinanceCharts+2 Today’s update pulls together the most important Merck stock news
29 November 2025
····
Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences Corporation (NASDAQ: EXAS) is trading near record highs as Wall Street shifts to “Hold,” merger-arb funds move in and shareholder lawyers start circling Abbott’s $21 billion bid. Exact Sciences Stock Price Snapshot for 25 November 2025 On Tuesday, 25 November 2025, Exact Sciences stock is trading around $101 per share, hovering just below its all‑time and 52‑week high near $102.ChartMill+1 That puts EXAS: At this point, EXAS is behaving less like a typical growth stock and more like a merger‑arbitrage trade: most of the upside is capped by the announced cash offer, while the remaining discount compensates investors
25 November 2025
·····
Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Dateline: November 24, 2025 Exact Sciences Corporation (NASDAQ: EXAS) stock is trading calmly near its takeover price today as Wall Street digests a flood of fresh analyst calls, legal scrutiny and local reaction to Abbott Laboratories’ multi‑billion‑dollar bid for the cancer‑diagnostics specialist. With shares hovering around $101 this afternoon and a cash offer on the table at $105 per share, Exact Sciences has effectively shifted from a high‑growth story to a merger‑arbitrage situation — but there’s still plenty happening around the name on November 24, 2025. Exact Sciences Investor Relations+1 Key takeaways for EXAS stock on November 24, 2025 Exact
24 November 2025
······
MOH Stock Today, Nov. 24, 2025: Molina Healthcare Rallies on ACA Subsidy Hopes as Lawsuits and Margin Pressures Linger

MOH Stock Today, Nov. 24, 2025: Molina Healthcare Rallies on ACA Subsidy Hopes as Lawsuits and Margin Pressures Linger

Molina Healthcare Inc. (NYSE: MOH) shares bounced higher on Monday as traders reacted to fresh headlines about a possible extension of Affordable Care Act (ACA) subsidies, even as the managed-care insurer continues to grapple with margin pressure, new class‑action lawsuits and a sharp rerating of its valuation. As of Monday’s close, MOH stock finished at $145.30, up about 2.6% for the day after trading between the low $140s and low $150s. StockAnalysis The move extends a modest rebound off recent lows but barely dents a brutal sell‑off: Molina remains more than 50% below its 52‑week high of $359.97, with a
24 November 2025
·
Hims & Hers Health (HIMS) Stock Today, November 23, 2025: Price, Buyback and GLP‑1 Risks

Hims & Hers Health (HIMS) Stock Today, November 23, 2025: Price, Buyback and GLP‑1 Risks

Hims & Hers Health (NYSE: HIMS) heads into the new week as one of the market’s most closely watched telehealth and weight‑loss plays — but also one of its most volatile. After Friday’s session (21 November 2025), HIMS closed at $34.71, up about 3.2% on the day. That puts the stock roughly 43–44% higher year‑to‑date, yet still almost 50% below its 2025 peak near $73.StockAnalysis+2PortfoliosLab+2 For today, 23 November 2025, the key fresh story isn’t a new earnings report or regulatory bombshell. Instead, the weekend news flow centers on: Below is a detailed rundown of where HIMS stands today and
23 November 2025
···
EXAS Stock Soars on Abbott Takeover Talks: Exact Sciences Jumps Over 20% on November 19, 2025

EXAS Stock Soars on Abbott Takeover Talks: Exact Sciences Jumps Over 20% on November 19, 2025

Exact Sciences Corporation (NASDAQ: EXAS) is surging today after reports that healthcare giant Abbott Laboratories is in advanced talks to acquire the cancer diagnostics specialist. Shares of EXAS spiked sharply intraday, briefly approaching new 52‑week highs as traders rushed into the name on renewed takeover speculation. Reuters+2Investing.com+2 Key points EXAS stock today: price, move, and trading activity According to Exact Sciences’ own investor relations quote page, EXAS was recently quoted at $81.79, up $12.11 or +17.38% versus yesterday’s close at $69.68. Intraday, the stock has traded between $69.11 and $89.67, with volume already above 10.4 million shares, far exceeding its recent averages. investor.exactsciences.com+1 Other real‑time feeds and market reports
19 November 2025
····
Cardinal Health (NYSE: CAH) Stock Soars to Record High on Blowout Earnings and Raised Outlook

Cardinal Health (NYSE: CAH) Stock Soars to Record High on Blowout Earnings and Raised Outlook

Stock Hits All-Time High After Earnings Surprise Cardinal Health’s stock price surged to an all-time high on October 30, 2025, after the company delivered much better-than-expected quarterly results. Shares soared ~13% in one day, briefly trading above $190 intraday and settling around $185 – levels never seen beforeinvesting.com247wallst.com. This spike extended Cardinal’s impressive rally (the stock is up over 50% year-on-year), as investors reacted enthusiastically to the latest earnings and outlook. The one-day jump came amid heavy trading volume and put Cardinal Health among the top gainers on the NYSE that day247wallst.com. The broad market was mixed, making Cardinal’s leap
30 October 2025
····
1 … 3 4 5 6

Stock Market Today

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
Ashtead shares closed Friday at 4,936p, up 1.09%, after the company bought 88,872 shares under its repurchase program. The group is set to shift its primary listing to New York on March 2, pending court approval, and will be removed from the FTSE UK index the same day. Ashtead paid a half-year dividend of 37.5 U.S. cents per share on Friday.
Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

7 February 2026
Beazley shares closed flat at 1,236 pence Friday as BlackRock disclosed a 6.55% stake and Vanguard reported 5.02%. Wellington Management cut its holding below 5%. The disclosures follow Zurich Insurance’s possible takeover offer of up to 1,335 pence per share, with a Feb. 16 deadline for a firm bid.
Go toTop